From Arizona's staggering 26,125 cases in 2022 to the heartbreakingly high mortality rate for certain vulnerable groups, these statistics reveal Valley Fever is far more than a regional nuisance—it's a rapidly growing health crisis demanding urgent attention.
Key Takeaways
- In 2022, Arizona reported 26,125 cases of coccidioidomycosis (Valley Fever), the highest annual total ever recorded in the state
- California's San Joaquin Valley accounted for approximately 70% of all Valley Fever cases in the state in 2021
- The national incidence of Valley Fever in the US increased from 5.3 cases per 100,000 in 2011 to 11.2 per 100,000 in 2021
- Common symptoms include fever (70%), cough (75%), and fatigue (90%) in symptomatic Valley Fever cases
- Erythema nodosum occurs in 20-30% of primary Valley Fever infections
- Arthralgias affect 40-50% of patients with acute Valley Fever
- Serum IgM detected in 70-90% of acute cases within 1-3 weeks
- IgG serology positive in >95% of disseminated Valley Fever by 6 weeks
- Chest X-ray shows infiltrates in 40% of symptomatic primary infections
- Azoles (fluconazole, itraconazole) are first-line for all forms except mild acute
- Fluconazole 400mg daily lifelong for coccidioidal meningitis (90% response)
- Amphotericin B (liposomal 5mg/kg/day) for severe acute or refractory disease
- N95 masks reduce exposure risk by 95% in high-risk occupations
- Avoid dusty activities during dry windy seasons (Oct-May) in endemic areas
- Wet soil before digging reduces spore aerosolization by 90%
Valley Fever cases are rising across the Southwestern United States and Mexico.
Diagnosis
1Serum IgM detected in 70-90% of acute cases within 1-3 weeks
Verified2IgG serology positive in >95% of disseminated Valley Fever by 6 weeks
Verified3Chest X-ray shows infiltrates in 40% of symptomatic primary infections
Verified4PCR sensitivity for Coccidioides in sputum is 60-80%
Directional5Culture positivity rate from respiratory specimens is 50-70% in acute disease
Single source6CSF glucose <40 mg/dL in 70% of coccidioidal meningitis cases
Verified7Complement fixation titer >1:16 predicts dissemination risk >20%
Verified8Tuberculin skin test false-positive in 20-25% due to cross-reactivity
Verified9Bronchoalveolar lavage PCR sensitivity 91% for pulmonary coccidioidomycosis
Directional10Histopathology shows spherules (10-80 μm) diagnostic in 100% of tissue biopsies
Single source11IDSA recommends two positive serologies for diagnosis confirmation
Verified12Urine antigen detection sensitivity 73% in disseminated disease, 27% in non-disseminated
Verified13False-negative serology in 5-10% of immunocompromised patients
Verified14CT scan shows nodules/cavities in 80% of chronic fibrocavitary disease
Directional15Eosinophilia (>5%) in peripheral blood in 25% of primary cases
Single source16Beta-D-glucan assay non-specific, positive in <50% Coccidioides cases
Verified17Spinal fluid CF titer >1:2 diagnostic for meningitis (sensitivity 75%)
Verified18Galaxy morphotype on fungal culture diagnostic for Coccidioides
Verified19Quantitative CF titer correlates with disease severity (r=0.7)
Directional20Immunodiffusion IgM sensitivity 83%, specificity 90%
Single source21PET-CT useful for detecting extrapulmonary dissemination in 90% cases
Verified22Skin testing no longer available since 1990s due to anaphylaxis risk
Verified23Enzyme immunoassay (EIA) screening followed by ID/CF reflex, per IDSA
Verified24Sputum culture conversion lags serology by 3-6 months in 70% cases
Directional25MRI shows basilar enhancement in 85% of coccidioidal meningitis
Single sourceDiagnosis Interpretation
Diagnosing Valley Fever is a masterclass in clinical detective work, requiring you to artfully combine a probabilistic jigsaw puzzle of imperfect tests—where a definitive answer often relies on finding the same antibody twice, seeing the fungus itself, or spotting its distinctive round shape in tissue.
Epidemiology
1In 2022, Arizona reported 26,125 cases of coccidioidomycosis (Valley Fever), the highest annual total ever recorded in the state
Verified2California's San Joaquin Valley accounted for approximately 70% of all Valley Fever cases in the state in 2021
Verified3The national incidence of Valley Fever in the US increased from 5.3 cases per 100,000 in 2011 to 11.2 per 100,000 in 2021
Verified4Kern County, California, had an incidence rate of 112.5 cases per 100,000 population in 2020
Directional5From 2018-2022, Pima County, Arizona, reported over 10,000 cases, averaging 2,000 annually
Single source6Sonora, Mexico, reported 1,200 Valley Fever cases in 2021 with an incidence of 28 per 100,000
Verified7In 2019, New Mexico had 1,147 confirmed cases, a 20% increase from 2018
Verified8Washington state saw 49 cases in 2022, mostly travel-related
Verified9Utah reported 128 cases in 2021, up from 68 in 2020
Directional10Texas had 85 cases in 2021, primarily in West Texas counties
Single source11Nevada reported 189 cases in 2022, incidence of 6.1 per 100,000
Verified12In 2020, Maricopa County, AZ, had 11,452 cases, 44% of state's total
Verified13Fresno County, CA, incidence was 94.3 per 100,000 in 2019
Verified14Over 60% of Valley Fever cases in Arizona occur in individuals aged 20-59 years
Directional15Males accounted for 61% of Valley Fever cases in California in 2021
Single source16African Americans have a dissemination rate of up to 15% for Valley Fever, compared to 1% in general population
Verified17Incidence among Filipinos in California is 165 per 100,000, 10 times higher than whites
Verified18Pregnant women have a 270% increased risk of disseminated Valley Fever
Verified19Diabetics have 3 times higher risk of severe Valley Fever
Directional20HIV patients have up to 50% mortality from disseminated coccidioidomycosis
Single source21Construction workers face 40 times higher risk of Valley Fever infection
Verified2260% of primary Valley Fever infections are asymptomatic
Verified23Annual US cases exceed 60,000, with underreporting estimated at 30-50%
Verified24Arizona's incidence peaked at 107 per 100,000 in 2011
Directional25California's cases tripled from 1,000 in 2000 to over 5,000 in 2019
Single source2640% of cases in Arizona are among non-residents/visitors
Verified27Children under 5 have lower dissemination rates (<0.5%)
Verified28Incidence in Arizona Hispanics is 1.5 times higher than non-Hispanics
Verified29Over 20,000 hospitalized Valley Fever cases annually in US Southwest
Directional3075% of US cases occur in Arizona and California
Single sourceEpidemiology Interpretation
While Arizona and California grapple with record-breaking, endemic hotspots where the dust literally has a bite, the national rise of Valley Fever reveals a disturbing expansion, disproportionately striking construction workers, diabetics, pregnant women, and Black and Filipino communities with devastating severity, proving this isn't just a regional dust devil but a growing national health crisis hiding in plain sight.
Prevention
1N95 masks reduce exposure risk by 95% in high-risk occupations
Verified2Avoid dusty activities during dry windy seasons (Oct-May) in endemic areas
Verified3Wet soil before digging reduces spore aerosolization by 90%
Verified4Pregnant women and immunocompromised avoid endemic areas
Directional5HEPA filters in HVAC systems reduce indoor spores by 99%
Single source6Annual serologic screening for high-risk workers (e.g., archeologists)
Verified7Paving or vegetating construction sites cuts cases by 70%
Verified8Stay indoors during dust storms, close windows, use AC with recirculate
Verified9No human vaccine available, animal vaccines in development (e.g., dogs)
Directional10Dust control measures in agriculture reduce farmworker incidence 50%
Single source11Military personnel in endemic areas: pre/post deployment serology
Verified12Avoid disturbing soil in endemic zones (AZ, CA, TX, NM)
Verified13Post-exposure prophylaxis not recommended routinely
Verified14Diabetes control reduces severe disease risk by 40%
Directional15Smoking cessation lowers dissemination risk in infected individuals
Single source16Early antifungal prophylaxis in high-risk post-exposure (e.g., transplant)
Verified17Public education campaigns reduced unreported cases by 15% in AZ
Verified18Fencing off construction sites with wind barriers effective
VerifiedPrevention Interpretation
For all the talk of our high-tech prowess, it's amusing yet sobering that the best defense against Valley Fever is a mixture of common sense, a good mask, and a garden hose.
Prognosis
1Annual cost of Valley Fever in AZ exceeds $100 million in medical care
VerifiedPrognosis Interpretation
While Arizona’s sunsets are famously free, catching a case of Valley Fever can quickly turn into a six-figure membership fee to our state's most unwelcome club.
Symptoms
1Common symptoms include fever (70%), cough (75%), and fatigue (90%) in symptomatic Valley Fever cases
Verified2Erythema nodosum occurs in 20-30% of primary Valley Fever infections
Verified3Arthralgias affect 40-50% of patients with acute Valley Fever
Verified4Chest pain reported in 35% of symptomatic cases
Directional5Headache occurs in 25% of Valley Fever patients, often mimicking meningitis
Single source6Dyspnea present in 20% of primary pulmonary coccidioidomycosis cases
Verified7Weight loss seen in 15-20% of acute cases lasting >1 month
Verified8Night sweats reported by 40% of symptomatic individuals
Verified9Rash (maculopapular) in 15-20% of cases
Directional10Disseminated disease presents with skin lesions in 15-20% of cases
Single source11Bone/joint pain in 20% of chronic pulmonary cases
Verified12Meningitis symptoms (severe headache, altered mental status) in 30-50% of CNS-disseminated cases
Verified13Pericarditis rare, <1% of cases, but can cause chest pain and effusion
Verified14Lymphadenopathy in 20% of primary infections on chest X-ray
Directional15Fatigue persists >3 months in 10-15% of cases
Single source16Myalgias in 50% of acute Valley Fever presentations
Verified17Sore throat/pharyngitis in 15% of cases
Verified18Pleural effusion on imaging in 5-10% of primary cases
Verified19Hilar adenopathy with infiltrates (classic "coin lesion") in 10-20%
Directional20Chronic fatigue syndrome-like symptoms in 5% post-primary infection
Single source21Anorexia and malaise in 60% of symptomatic patients
Verified22Splenic abscess rare, <0.1%, but seen in disseminated disease
VerifiedSymptoms Interpretation
If Valley Fever were throwing a party, fatigue would be the obnoxiously persistent guest who arrives first (90% of the time), brings a hacking cough (75%) and a fever (70%), and then overstays his welcome in one out of ten cases, while the other symptoms—from night sweats to bone-deep aches—pop in and out with the erratic frequency of less committed attendees, and the rare but serious ones, like meningitis or a splenic abscess, crash the event like uninvited troublemakers.
Treatment
1Azoles (fluconazole, itraconazole) are first-line for all forms except mild acute
Verified2Fluconazole 400mg daily lifelong for coccidioidal meningitis (90% response)
Verified3Amphotericin B (liposomal 5mg/kg/day) for severe acute or refractory disease
Verified4Surgical resection for localized pulmonary nodules/cavities in 80% cure rate
Directional5Itraconazole 200mg BID for chronic pulmonary coccidioidomycosis (70% response)
Single source6Voriconazole as salvage therapy, response 60% in azole failures
Verified7Posaconazole effective for osteoarticular disease (71% cure)
Verified8Mild acute primary infection self-resolves in 90%, no antifungals needed
Verified9Intrathecal amphotericin for refractory meningitis (shunt reservoir)
Directional10Relapse rate 25-30% after azole discontinuation in disseminated disease
Single source11Corticosteroids adjunct for severe pulmonary disease with hypoxia
Verified12Isavuconazole non-inferior to amphotericin in severe cases (VITAL trial subset)
Verified13Duration of therapy for bone disease: 12+ months, cure 60-80%
Verified14Pregnancy: amphotericin B preferred (category B), azoles teratogenic
Directional15Monitoring LFTs monthly on azoles, hepatotoxicity in 5-10%
Single source16Therapeutic drug monitoring for itraconazole (target 1-2 mcg/mL)
Verified17Echinocandins ineffective due to no beta-glucan in spherule wall
Verified18Shunt placement for hydrocephalus in 40% of meningitis cases
Verified19Overall mortality 1% for primary, 25-50% for disseminated untreated
Directional20Vaccine trials (e.g., spherulin-derived) showed 80% efficacy in past, not available
Single sourceTreatment Interpretation
For all its desert-dust origins, Valley Fever presents a medical chessboard where the first move is often a simple azole, but the endgame can require everything from lifelong pills and brain shunts to salvage drugs and surgery, reminding us that while most infections shrug off on their own, the ones that don't play for keeps.
Sources & References
- Reference 1AZDHSazdhs.govVisit source
- Reference 2CDPHcdph.ca.govVisit source
- Reference 3CDCcdc.govVisit source
- Reference 4KERNPUBLICHEALTHkernpublichealth.comVisit source
- Reference 5PIMApima.govVisit source
- Reference 6NCBIncbi.nlm.nih.govVisit source
- Reference 7NMHEALTHnmhealth.orgVisit source
- Reference 8DOHdoh.wa.govVisit source
- Reference 9HEALTHhealth.utah.govVisit source
- Reference 10DSHSdshs.texas.govVisit source
- Reference 11DPBHdpbh.nv.govVisit source
- Reference 12MARICOPAmaricopa.govVisit source
- Reference 13FRESNOHEALTHfresnohealth.netVisit source
- Reference 14WWWNCwwwnc.cdc.govVisit source
- Reference 15PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 16ATSJOURNALSatsjournals.orgVisit source
- Reference 17ACADEMICacademic.oup.comVisit source
- Reference 18JOURNALSjournals.asm.orgVisit source
- Reference 19NEJMnejm.orgVisit source
- Reference 20PEDIATRICSpediatrics.aappublications.orgVisit source
- Reference 21MAYOCLINICmayoclinic.orgVisit source
- Reference 22THORACICthoracic.orgVisit source
- Reference 23DERMNETNZdermnetnz.orgVisit source
- Reference 24IDSOCIETYidsociety.orgVisit source
- Reference 25AHAJOURNALSahajournals.orgVisit source
- Reference 26RADIOPAEDIAradiopaedia.orgVisit source
- Reference 27EMEDICINEemedicine.medscape.comVisit source
- Reference 28UPTODATEuptodate.comVisit source
- Reference 29PUBSpubs.rsna.orgVisit source
- Reference 30THORAXthorax.bmj.comVisit source
- Reference 31MERCKMANUALSmerckmanuals.comVisit source
- Reference 32MERIDIANmeridian.allenpress.comVisit source
- Reference 33MYmy.clevelandclinic.orgVisit source
- Reference 34JOURNALSjournals.lww.comVisit source
- Reference 35CIDcid.oxfordjournals.orgVisit source
- Reference 36MARCHOFDIMESmarchofdimes.orgVisit source
- Reference 37EPAepa.govVisit source
- Reference 38OSHAosha.govVisit source
- Reference 39WEATHERweather.govVisit source
- Reference 40HEALTHhealth.milVisit source
- Reference 41BLMblm.govVisit source
- Reference 42CPWRcpwr.comVisit source